Skip to main content

Laboratory Corporation of America Holdings Value Stock - Dividend - Research Selection

Laboratory

ISIN: US50540R4092 , WKN: 895308

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women\'s health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Ultima Genomics releases groundbreaking TRACERx MRD data showing ppmSeq performance and unveils clinical progress of whole genome sequencing at inaugural global MRD Symposium at AACR 2026

2026-04-17
Ultima Genomics, a developer of an innovative, ultra-high throughput sequencing architecture today announced key milestones for its ppmSeq® technology with a growing body of evidence from data presented across six abstracts, including an oral session and a plenary session at the 2026 AACR Annual Meeting in San Diego, taking place April 17–22, 2026. Highlighting the program will be initial TRACERx MRD data showcasing the performance of ppmSeq relative to ultrasensitive bespoke panels. Data from c

Tempus AI Expands Strategic Partnership Amid Oncology Boom

2026-04-16
TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.

Labcorp’s Rapid Fentanyl Test Clearance And What It Means For Valuation

2026-04-16
Labcorp Holdings (NYSE:LH) has received the first FDA clearance for a rapid fentanyl urine test for use in emergency and clinical settings. The test is designed to give healthcare teams quick, reliable information on fentanyl exposure so they can act faster in acute care situations. This clearance highlights Labcorp's role in addressing the ongoing opioid crisis through expanded diagnostic capabilities. For investors tracking Labcorp Holdings at a share price of $266.73, this FDA clearance...

How Investors Are Reacting To Labcorp (LH) AI-Powered Real-World Data Push In Complex Disease Research

2026-04-15
Earlier this month, Labcorp announced an AI-powered real-world data platform, built with Amazon Web Services and Datavant, to accelerate analysis of deidentified Alzheimer’s-related healthcare data for researchers and biopharma customers. In parallel, Labcorp and Children’s Hospital of Philadelphia agreed to build a nationwide pediatric diagnostics innovation pipeline, highlighting how the company is pairing advanced data analytics with highly specialized testing to broaden its role in...

Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes

2026-04-15
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Labcorp Fentanyl Urine Visual Test, the first U.S. Food and Drug Administration (FDA)-cleared rapid fentanyl test of its kind manufactured in the United States. The test delivers results in just 10 minutes, giving healthcare providers fast, actionable answers when treating suspected fentanyl exposure in emergency departments, hospitals and clinics.

Labcorp Launches FDA-Cleared Fentanyl Urine Test Delivering Results In 10 Minutes For Rapid Clinical Screening

2026-04-15

Labcorp Introduces Ai-Powered Real-World Data Platform with Aws and Datavant

2026-04-14
Labcorp announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster. Developed with Amazon Web...

Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research

2026-04-14
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster. Developed with Amazon Web Services (AWS) and Datavant, the platform provides access to large, diverse datasets and advanced analytics—using deidentified, privacy-protected healthcare data—designed to accelerate scientific discovery, shorten d

Labcorp Launches AI-Powered, Real-World Data Platform Developed With AWS And Datavant That Aims To Analyze Alzheimer's Disease-Related Data Faster

2026-04-14
Developed with Amazon Web Services (AWS) and Datavant, the platform provides access to large, diverse datasets and advanced analytics—using deidentified, privacy-protected healthcare data—designed to accelerate

Labcorp and Children's Hospital of Philadelphia Announces Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide

2026-04-13
Labcorp and Children's Hospital of Philadelphia announced a strategic collaboration to accelerate the discovery, development and nationwide availability of specialized pediatric diagnostics. By...